Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06603571 · ClinicalTrials.gov registry record · Phase 2
A Study to Investigate Weight Management With LY3841136 and Tirzepatide (LY3298176), Alone or in Combination, in Adult Participants With Obesity or Overweight With Type 2 Diabetes
A Phase 2 study of Obesity and Overweight, sponsored by Eli Lilly and Company.
- Active
- Registry status
- Phase 2
- Development phase
- 350
- Enrollment target
- 20
- Study locations
NCT06603571: Active Phase 2 study of Obesity and Overweight, sponsored by Eli Lilly and Company.
NCT06603571 is a Phase 2 study of Obesity and Overweight that is active but no longer recruiting, run by Eli Lilly and Company. The registered enrollment target is 350 participants, below the 819-participant average among 1,053 other Obesity trials with a reported enrollment target (57% lower). The trial reports 20 study locations across 7 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06603571, a Phase 2 study of Obesity and Overweight, is active but no longer recruiting, sponsored by Eli Lilly and Company.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 350 participants
- Enrollment target
- 20
- Study locations
Study Summary
The main purpose of this study, performed under the master protocol W8M-MC-CWMM (NCT06143956), is to investigate the safety and efficacy of LY3841136 for chronic weight management alone or in combination with Tirzepatide across a wide dose range in participants with Type 2 Diabetes. Participation in the study will last about 64 weeks.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Tirzepatide
- DRUG LY3841136
Study Locations (20)
Florida
- Northeast Research Institute (NERI) - Fleming Island
- Indago Research & Health Center, Inc - Hialeah
- New Horizon Research Center - Miami
- Suncoast Clinical Research, Inc. - New Port Richey
- Charter Research - Winter Park - Orlando
- Charter Research - Lady Lake - The Villages
Arizona
- The Institute for Liver Health II dba Arizona Clinical Trials - Mesa - Chandler
- HOPE Research Institute - Phoenix
- Headlands Research - Scottsdale - Scottsdale
- The Institute for Liver Health II dba Arizona Liver Health-Tucson - Tucson
California
- NorCal Medical Research, Inc - Greenbrae
- Velocity Clinical Research, Huntington Park - Huntington Park
- Peninsula Research Associates - Rolling Hills Estates
- Diablo Clinical Research, Inc. - Walnut Creek
Illinois
- Great Lakes Clinical Trials - Andersonville - Chicago
- Great Lakes Clinical Trials - Ravenswood - Chicago
- NorthShore University Health System - Skokie
Connecticut
- Stamford Therapeutics Consortium - Stamford
Idaho
- Medical Research Partners - Ammon
Iowa
- Iowa Diabetes and Endocrinology Research Center - West Des Moines
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 350 participants |
| Start Date | 2024-09-20 |
| Est. Completion | 2026-08 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06603571
The ClinicalTrials.gov registry entry for NCT06603571 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 350 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 819-participant average among 1,053 other Obesity trials with a reported enrollment target (57% lower). The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Obesity appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.
NCT06603571 reports 20 study locations spanning 7 distinct geographic areas - top geographies include Florida, Arizona, California.
Frequently Asked Questions
What is clinical trial NCT06603571 about?
NCT06603571 is a clinical study titled "A Study to Investigate Weight Management With LY3841136 and Tirzepatide (LY3298176), Alone or in Combination, in Adult Participants With Obesity or Overweight With Type 2 Diabetes". The main purpose of this study, performed under the master protocol W8M-MC-CWMM (NCT06143956), is to investigate the safety and efficacy of LY3841136 for chronic weight management alone or in combination with Tirzepatide across a wide dose range in participants with Type 2 Diabetes. Participation in...
What is the current status of trial NCT06603571?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 350 participants. The study started on 2024-09-20. Estimated completion is 2026-08.
What conditions does trial NCT06603571 study?
This clinical trial studies the following conditions: Obesity, Overweight.
What interventions are being tested in trial NCT06603571?
The interventions under investigation include: Placebo (DRUG), Tirzepatide (DRUG), LY3841136 (DRUG).
Who is sponsoring clinical trial NCT06603571?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06603571 being conducted?
This trial has 20 study locations across Arizona, California, Connecticut, Florida, Idaho. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Obesity
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
TIRzepatide for the Treatment of Obesity in Patients With Atrial Fibrillation
RECRUITING · Phase 2
-
Tirzepatide: Reversal of Lipotoxicity and Adipose Tissue Dysfunction in Humans With Overweight/Obesity
RECRUITING · Phase 2
-
Convergent Mechanisms Underlying Reprometabolic Syndrome in Women
RECRUITING · Phase 2
-
Arterial Destiffening Effects of SGLT2 Inhibition in Veterans With Obesity
RECRUITING · Phase 2
-
A Master Protocol Study (LY900038) of Multiple Intervention-Specific-Appendices (ISAs) in Adult Participants With Obesity or Overweight
RECRUITING · Phase 2
-
Pharmacological and Behavioral Treatment After Bariatric Surgery
RECRUITING · Phase 2
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.